Skip to content

Effect of zinc containing herbomineral compound prepared by two different methods in patients of Diabetes Mellitus

Role of Mardana Samskara on therapeutic efficacy of Laghu Malini Vasanta Rasa in Management of Madhumeha â??Type 2 DM.

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/07/004761
Enrollment
100
Registered
2014-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients suffering from Madhumeha

Interventions

Intervention1: LaghuMaliniVasanta Rasa prepared by Yashada Bhasma as per reference of (Yoga Ratnakar jwaradhikara): 250 mg tablet of LMV ( 125 mg of Laghu Malini Vasanta Rasa + 125 mg of Pippali Curn

Sponsors

Dept of RS BK IPGTRA Gujarat Ayurved University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 40 years to 70 years Patients having chief & associated complaints of Madhumeha (Avilamutrata, Pipasa-adhikya, Kshudha-adhikya, etc.). Known patient of type 2 diabetes mellitus, and also the patients preliminarily diagnosed type 2 diabetes mellitus on the basis of signs and symptoms of the disease will be confirmed by FBS and PPBS. Blood sugar â?? Fasting more than 126 and equal to or less than 200 mg/dl or PP more than 200 mg/dl

Exclusion criteria

Exclusion criteria: 1. Age below 40 and above 70 years. Blood sugar â?? Fasting less than or equal to 126 and more than 200 mg/dl or PPBS less than 200 mg/dl. 2. Malignant and accelerated hypertensive 3. CVS disorder (CAD) 4. Pregnant woman and planning to be pregnant within six months 5. Lactating mother 6. Secondary Diabetes mellitus 7. Patient undergoing regular treatment for Diabetes or any other severe illness 8. CNS disorder e.g. encephalopathy

Design outcomes

Primary

MeasureTime frame
Improvement in the signs and symptoms of the disease as per Ayurvedic and Allopathic texts Investigations conducted before and after the treatment Timepoint: 8 weeks

Secondary

MeasureTime frame
exacerbation in signs and symptomsTimepoint: 8 weeks

Countries

India

Contacts

Public ContactProf PK Prajapati

IPGTRA

prajapati.pradeep1@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026